Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Operating Margin (2016 - 2025)

Historic Operating Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 32.29%.

  • Theravance Biopharma's Operating Margin rose 319500.0% to 32.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.85%, marking a year-over-year increase of 287600.0%. This contributed to the annual value of 72.92% for FY2024, which is 246600.0% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Operating Margin is 32.29%, which was up 319500.0% from 10.4% recorded in Q2 2025.
  • Theravance Biopharma's 5-year Operating Margin high stood at 10.4% for Q2 2025, and its period low was 1540.08% during Q1 2022.
  • Its 5-year average for Operating Margin is 248.83%, with a median of 110.16% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 42433100bps in 2021, then tumbled by -9516500bps in 2022.
  • Over the past 5 years, Theravance Biopharma's Operating Margin (Quarter) stood at 375.8% in 2021, then skyrocketed by 68bps to 119.0% in 2022, then soared by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then skyrocketed by 34bps to 32.29% in 2025.
  • Its Operating Margin was 32.29% in Q3 2025, compared to 10.4% in Q2 2025 and 93.8% in Q1 2025.